- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04172714
Low-dose Y90 Treatment Planning for HCC
Theragnostic Low Dose Y90 Microspheres for Personalized Y90 Radioembolization Dosimetry Planning
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
Atlanta, Georgia, United States, 30308
- Emory University Midtown
-
Atlanta, Georgia, United States, 30322
- Emory Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults ≥ 18 years
- Life expectancy of 6 months or more as determined by the investigator
- HCC confirmed by Liver Reporting & Data System (LIRADS) on MRI or CT
- Must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) with CT scan, MRI, or calipers by clinical exam. See Section 12 (Measurement of Effect) for the evaluation of measurable disease.
- ≤3 lesions
- Longest dimension of the largest lesion ≤7cm
- Single lobe disease
- No significant extrahepatic metastatic disease
- Barcelona Clinic Liver Cancer Stage A, B or C
- ECOG < 2 (Appendix A)
- Lesion(s) <50% of liver volume
- Bilirubin ≤ 2 mg/dL
- Albumin ≥ 3 g/dL
- PT/INR < 2
- AST/ALT ≤ 3 institutional upper limit of normal (ULN)
- Platelet count > 50,000/mcL
- Lung shunt fraction of <20% by planar MAA if dose modification results in inadequate dose delivered to the tumor(s)
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥ 12 week before the start of study therapy. Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions.
u. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation. v. The effects of Y90 microspheres on the developing human fetus are unknown. For this reason female of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy. Winship Protocol #: RAD4784 Version Date: Aug 22, 2019 20 | P a g e w. FCBP and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of [IND Agent] administration. A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months
Exclusion Criteria:
- An individual who does not meet all the inclusion criteria in section.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Second mapping with low-dose Y90
Patients will undergo standard of care mapping study with 99TC-MAA to plan for Y90 radioembolization therapy.
Additionally,non-standard of care, intervention will be to do a second mapping study using SIR-spheres microspheres with low-dose Y90 (15 mCi) before the therapeutic Y90 radioembolization.
|
SIR-Spheres® Y-90 resin microspheres consist of biocompatible polymer resin microspheres of a median diameter of 32.5 microns (range between 20 and 60 microns) loaded with yttrium-90 (beta radiation penetrating an average of 2.5 mm in tissue to destroy tumor cells).
The resin microspheres are small enough to become lodged in the arterioles within the growing rim of the tumor but are too large to pass through the capillaries and into the venous system.
Since yttrium-90 has a half-life of 64.1 hours, most of the radiation (94%) is delivered to the tumor over 11 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lung Shunt Fraction (LSF) Ratio
Time Frame: Baseline
|
Y-90 radioembolization treatment requires estimating the activity shunted from the liver to the lungs, referred to as a lung shunt fraction (LSF).
It is expressed in ratios, with higher ratio meaning a higher transit of Y-90 to the lungs (worse outcome) and lower ratio, lower transit of Y-90 to the lungs (better outcome).
|
Baseline
|
Tumor to Normal Liver Activity Ratio (TNR)
Time Frame: Baseline
|
The ratios of the tumor-to-normal liver parenchymal radioactivity uptake count will be measured.
TNR values will be calculated by dividing the mean count of the tumorous volume of interest (VOI) by the mean count of normal liver.
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Tumor Response Using Imaging Modified Response Criteria in Solid Tumors (m-RECIST) Post Y90 Embolization
Time Frame: 6 months post intervention
|
To identify tumor dose response threshold (TDRT) using Imaging Modified Response Criteria in Solid Tumors (m-RECIST), that is a method for measuring treatment response and measure of antitumor activity of cytotoxic drugs.
This is measured using imaging: CT or MRI.
The overall response is a combination of responses in each category: complete response (disappearance of any intramural arterial enhancement in all target lesions), partial response (at least 30% decrease in the sum of the diameters of viable target lesions), stable disease (any cases that do not qualify for either partial response or progressive disease) or progressive disease (an increase of at least 20% in the sum of the diameters of viable, enhancing target lesions, taking as a reference the smallest sum of the diameters of viable target lesions recorded since treatment started).
|
6 months post intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nima Kokabi, MD, Emory University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00112192
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HCC
-
University of PisaAzienda Ospedaliera Città della Salute e della Scienza di Torino; Fondazione... and other collaboratorsRecruiting
-
Seoul National University HospitalPhilips HealthcareCompleted
-
Huazhong University of Science and TechnologyUnknown
-
Taipei Medical University WanFang HospitalTerminated
-
Leiden University Medical CenterMedtronic; ZonMw: The Netherlands Organisation for Health Research and Development and other collaboratorsCompletedHCC | Early Stage HCCNetherlands
-
Qianfoshan HospitalNot yet recruiting
-
Xuhua DuanRecruiting
-
Ain Shams UniversityCompleted
-
Shenyang Tenth People's HospitalBeijing Tsinghua Changgeng HospitalNot yet recruiting
Clinical Trials on SIR-Spheres microspheres
-
Sirtex MedicalTerminatedCarcinoma, Hepatocellular | HepatomaUnited States
-
SCRI Development Innovations, LLCSirtex MedicalCompleted
-
Sirtex MedicalCompletedColorectal Cancer | Liver Metastases | Colorectal CarcinomaUnited States, Israel, Australia, Belgium, New Zealand, Spain, Germany, Switzerland, Italy, France, Poland
-
Sirtex MedicalCompletedHepatocellular CarcinomaGermany, Spain
-
Cardiovascular and Interventional Radiological...Completed
-
Sirtex MedicalCompletedColorectal Cancer MetastaticUnited States, France, Korea, Republic of, Australia, Israel, Singapore, Belgium, Taiwan, Spain, New Zealand, Portugal, Germany, Italy
-
Cardiovascular and Interventional Radiological...Completed
-
SCRI Development Innovations, LLCIpsenTerminatedGastrointestinal Neoplasms | Neuroendocrine Tumors | Carcinoid TumorsUnited States
-
GrandPharma (China) Co., Ltd.Not yet recruiting
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Active, not recruitingStage IV Uveal MelanomaUnited States